Study of INCA036978 in Participants With Myeloproliferative Neoplasms

NCT07441694 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

218

Enrollment

INDUSTRY

Sponsor class

Conditions

Myeloproliferative Neoplasms

Interventions

DRUG: INCA036978
DRUG: Standard disease-directed therapy

Sponsor

Incyte Corporation